Dr. Rizzo on Impact of Age on Survival Outcomes in MDS After HCT

Video

J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes who receive a hematopoietic cell transplant.

J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes (MDS) who receive a hematopoietic cell transplant (HCT).

Hypomethylating agents can create disease modification for patients with MDS, Rizzo explains. However, allogeneic HCT has proven to be the only curative therapy for this disease.

In patients with MDS over the age of 65, Medicare coverage for HCT was found to be unavailable, Rizzo explains. In disagreement with this decision, researchers conducted a study comparing the survival outcomes of patients aged 55 to 64 with patients over 65, both of whom received HCT. Findings showed that there was not a higher 100-day mortality in the older patient population, Rizzo adds. The study demonstrates that age alone should not be a determinant when considering HCT for patients with MDS.

Related Videos
Jorge J. Castillo, MD,
Heinz-Josef Lenz, MD, FACP
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Omid Hamid, MD, professor, medicine, Cedars-Sinai; director, Clinical Research and Immunotherapy, director, Cutaneous Oncology and Melanoma, The Angeles Clinic and Research Institute
Christina L. Roland, MD, MS, FACS
Ashish Saxena, MD, PhD
Shruti Tiwari, MD
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine